These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24653483)

  • 21. A review of rapid-onset opioids for breakthrough pain in patients with cancer.
    Simon SM; Schwartzberg LS
    J Opioid Manag; 2014; 10(3):207-15. PubMed ID: 24944071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis.
    Jandhyala R; Fullarton J
    BMJ Support Palliat Care; 2012 Jun; 2(2):156-62. PubMed ID: 24654058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
    Alberts DS; Smith CC; Parikh N; Rauck RL
    Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Hashemi M; Zali A; Golmakani E; Delshad MH; Shadnoush M; Akbari ME
    Daru; 2021 Jun; 29(1):51-59. PubMed ID: 33475984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies.
    Nalamachu SR; Rauck RL; Wallace MS; Hassman D; Howell J
    Pain Pract; 2012 Jul; 12(6):449-56. PubMed ID: 22226371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
    Mercadante S; Adile C; Cuomo A; Aielli F; Cortegiani A; Casuccio A; Porzio G
    J Pain Symptom Manage; 2015 Nov; 50(5):579-86. PubMed ID: 26303188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacoeconomics of breakthrough cancer pain.
    Kuo KL; Saokaew S; Stenehjem DD
    J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):167-75. PubMed ID: 23688496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Barriers to the use of buccal and intranasal fentanyl for breakthrough pain in paediatric palliative care: an exploratory survey.
    Harrop E; Jamieson L; Choy TH; Ho WHP; Wong ICK
    BMJ Support Palliat Care; 2018 Sep; 8(3):355-356. PubMed ID: 28801316
    [No Abstract]   [Full Text] [Related]  

  • 31. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
    Parikh N; Goskonda V; Chavan A; Dillaha L
    Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New formulations of fentanyl for acute pain management.
    Paech MJ; Bloor M; Schug SA
    Drugs Today (Barc); 2012 Feb; 48(2):119-32. PubMed ID: 22384452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
    Dietrich E; Gums JG
    Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain.
    Davies A; Kleeberg UR; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
    Support Care Cancer; 2015 Jul; 23(7):2135-43. PubMed ID: 25556611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
    Romualdi P; Candeletti S
    Minerva Med; 2016 Apr; 107(2):114-22. PubMed ID: 27064584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
    Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
    Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The management of wound-related procedural pain (volitional incident pain) in advanced illness.
    Gallagher R
    Curr Opin Support Palliat Care; 2013 Mar; 7(1):80-5. PubMed ID: 23150425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain.
    Davies A; Mundin G; Vriens J; Webber K; Buchanan A; Waghorn M
    J Pain Symptom Manage; 2016 Mar; 51(3):538-45. PubMed ID: 26706627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fentanyl pectin nasal spray for breakthrough cancer pain.
    Torres LM; Trinidad JM; Calderón E; Benitez D; Perelman M
    Int J Palliat Nurs; 2015 Mar; 21(3):114-6. PubMed ID: 25815759
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.